Immunogenic Compositions Comprising Conjugated Capsular Saccharide Antigens and Uses Thereof
US-2015202309-A1 · Jul 23, 2015 · US
Glycoconjugation processes and compositions
US10583187B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10583187-B2 |
| Application number | US-201815946664-A |
| Country | US |
| Kind code | B2 |
| Filing date | Apr 5, 2018 |
| Priority date | Aug 16, 2012 |
| Publication date | Mar 10, 2020 |
| Grant date | Mar 10, 2020 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The invention provides eTEC linked glycoconjugates comprising a saccharide covalently conjugated to a carrier protein through a (2-((2-oxoethyl)thio)ethyl)carbamate (eTEC) spacer, immunogenic compositions comprising such glycoconjugates, and methods for the preparation and use of such glycoconjugates and immunogenic compositions.
First claim
Opening claim text (preview).
The invention claimed is: 1. A glyconconjugate comprising a Streptococcus pneumoniae -derived capsular polysaccharide conjugated to a carrier protein through a (2-((2-oxoethyl)thio)ethyl)carbamate (eTEC) spacer, wherein said glyconconjugate comprises less than about 15% free saccharide. 2. A glyconconjugate according to claim 1 , wherein said Streptococcus pneumoniae -derived capsular polysaccharide is a Pn-serotype 33F capsular polysaccharide. 3. A glyconconjugate according to claim 1 , wherein said Streptococcus pneumoniae -derived capsular polysaccharide is a Pn-serotype 22F capsular polysaccharide. 4. A glyconconjugate according to claim 1 , wherein said Streptococcus pneumoniae -derived capsular polysaccharide is a Pn-serotype 10A capsular polysaccharide. 5. A glyconconjugate according to claim 1 , wherein said Streptococcus pneumoniae -derived capsular polysaccharide is a Pn-serotype 11A capsular polysaccharide. 6. An immunogenic composition comprising a glycoconjugate according to claim 1 and a pharmaceutically acceptable excipient, carrier, or diluent. 7. An immunogenic composition according to claim 6 further comprising an additional antigen. 8. An immunogenic composition according to claim 7 , wherein the additional antigen comprises a glycoconjugate of a Streptococcus pneumoniae -derived capsular polysaccharide selected from the group consisting of Pn-serotype 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 22F, 23F and 33F capsular polysaccharides. 9. An immunogenic composition according to claim 8 further comprising at least one adjuvant. 10. An immunogenic composition according to claim 1 , wherein said carrier protein is CRM 197 .
Assignees
Inventors
Classifications
Immunostimulants · CPC title
Antibacterial agents · CPC title
Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics · CPC title
Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins · CPC title
Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10583187B2 cover?
- The invention provides eTEC linked glycoconjugates comprising a saccharide covalently conjugated to a carrier protein through a (2-((2-oxoethyl)thio)ethyl)carbamate (eTEC) spacer, immunogenic compositions comprising such glycoconjugates, and methods for the preparation and use of such glycoconjugates and immunogenic compositions.
- Who is the assignee on this patent?
- Pfizer
- What technology area does this patent fall under?
- Primary CPC classification A61K47/64. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Mar 10 2020 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 2 related publications on this page (citations in our corpus or others sharing the same primary CPC).